Roy H Perlis1. 1. Center for Experimental Drugs and Diagnostics, Department of Psychiatry and Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. rperlis@partners.org
Abstract
BACKGROUND: Early identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice. METHODS: Data were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials. RESULTS: A logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches--a naïve Bayes classifier and a support vector machine, and a random forest model--was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk. CONCLUSION: Risk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.
BACKGROUND: Early identification of depressed individuals at high risk for treatment resistance could be helpful in selecting optimal setting and intensity of care. At present, validated tools to facilitate this risk stratification are rarely used in psychiatric practice. METHODS: Data were drawn from the first two treatment levels of a multicenter antidepressant effectiveness study in major depressive disorder, the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) cohort. This cohort was divided into training, testing, and validation subsets. Only clinical or sociodemographic variables available by or readily amenable to self-report were considered. Multivariate models were developed to discriminate individuals reaching remission with a first or second pharmacological treatment trial from those not reaching remission despite two trials. RESULTS: A logistic regression model achieved an area under the receiver operating characteristic curve exceeding .71 in training, testing, and validation cohorts and maintained good calibration across cohorts. Performance of three alternative models with machine learning approaches--a naïve Bayes classifier and a support vector machine, and a random forest model--was less consistent. Similar performance was observed between more and less severe depression, men and women, and primary versus specialty care sites. A web-based calculator was developed that implements this tool and provides graphical estimates of risk. CONCLUSION: Risk for treatment resistance among outpatients with major depressive disorder can be estimated with a simple model incorporating baseline sociodemographic and clinical features. Future studies should examine the performance of this model in other clinical populations and its utility in treatment selection or clinical trial design.
Authors: P W Lavori; A J Rush; S R Wisniewski; J Alpert; M Fava; D J Kupfer; A Nierenberg; F M Quitkin; H A Sackeim; M E Thase; M Trivedi Journal: Biol Psychiatry Date: 2001-11-15 Impact factor: 13.382
Authors: Timothy Petersen; George I Papakostas; Yasmin Mahal; Wendy M Guyker; Erin C Beaumont; Jonathan E Alpert; Maurizio Fava; Andrew A Nierenberg Journal: Eur Psychiatry Date: 2004-06 Impact factor: 5.361
Authors: A John Rush; Madhukar H Trivedi; Hicham M Ibrahim; Thomas J Carmody; Bruce Arnow; Daniel N Klein; John C Markowitz; Philip T Ninan; Susan Kornstein; Rachel Manber; Michael E Thase; James H Kocsis; Martin B Keller Journal: Biol Psychiatry Date: 2003-09-01 Impact factor: 13.382
Authors: A John Rush; Maurizio Fava; Stephen R Wisniewski; Philip W Lavori; Madhukar H Trivedi; Harold A Sackeim; Michael E Thase; Andrew A Nierenberg; Frederic M Quitkin; T Michael Kashner; David J Kupfer; Jerrold F Rosenbaum; Jonathan Alpert; Jonathan W Stewart; Patrick J McGrath; Melanie M Biggs; Kathy Shores-Wilson; Barry D Lebowitz; Louise Ritz; George Niederehe Journal: Control Clin Trials Date: 2004-02
Authors: Mark J Niciu; David A Luckenbaugh; Dawn F Ionescu; Sara Guevara; Rodrigo Machado-Vieira; Erica M Richards; Nancy E Brutsche; Neal M Nolan; Carlos A Zarate Journal: J Clin Psychiatry Date: 2014-05 Impact factor: 4.384
Authors: James W Murrough; Katherine E Burdick; Cara F Levitch; Andrew M Perez; Jess W Brallier; Lee C Chang; Alexandra Foulkes; Dennis S Charney; Sanjay J Mathew; Dan V Iosifescu Journal: Neuropsychopharmacology Date: 2015-03-13 Impact factor: 7.853
Authors: Colm O'Dushlaine; Stephan Ripke; Douglas M Ruderfer; Steven P Hamilton; Maurizio Fava; Dan V Iosifescu; Isaac S Kohane; Susanne E Churchill; Victor M Castro; Caitlin C Clements; Sarah R Blumenthal; Shawn N Murphy; Jordan W Smoller; Roy H Perlis Journal: Biol Psychiatry Date: 2014-01-19 Impact factor: 13.382
Authors: Callie L McGrath; Mary E Kelley; Boadie W Dunlop; Paul E Holtzheimer; W Edward Craighead; Helen S Mayberg Journal: Biol Psychiatry Date: 2013-12-19 Impact factor: 13.382